Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis

Kidney International

Volumn 88, Issue 6, 2015, Pages 1392-1401

  Barbour, Sean J ^a,b   Cattran, Daniel C ^c,d   Espino Hernandez, Gabriela ^b   Hladunewich, Michelle A ^c,d   Reich, Heather N ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC Provincial Renal Agency   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Toronto GN Registry   (Canada)

Author keywords

Confounder; Glomerulonephritis; Prediction; Proteinuria; Renal progression

Indexed keywords

ADULT; ARTICLE; BODY SURFACE; DISEASE REGISTRY; END STAGE RENAL DISEASE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; IDIOPATHIC DISEASE; IMMUNOGLOBULIN A NEPHROPATHY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; METRIC SYSTEM; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 84949890243     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.241     Document Type: Article

References (31)

1. Leaf DE, Appel GB, Radhakrishnan J. Glomerular disease: why is there a dearth of high quality clinical trials? Kidney Int 2010; 78: 337-342
2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int 2012; S2: 139-274
3. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 2012; 59: 865-873
4. Reich HN, Troyanov S, Scholey JW et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18: 3177-3183
5. Troyanov S, Wall CA, Miller JA et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66: 1199-1205
6. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32: 72-79
7. Troyanov S, Wall CA, Miller JA et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16: 1061-1068
8. Lv J, Zhang H, Chen Y et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009; 53: 26-32
9. Hladunewich MA, Troyanov S, Calafati J et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009; 4: 1417-1422
10. Rydel JJ, Korbet SM, Borok RZ et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995; 25: 534-542
11. Cattran DC, Pei Y, Greenwood CM et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901-907
12. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490
13. Cattran DC, Reich HN, Beanlands HJ et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008; 23: 2247-2253
14. Coppo R, Peruzzi L, Amore A et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888
15. Stirling CM, Mathieson P, Boulton-Jones JM et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 2005; 98: 443-449
16. Deegens JK, Steenbergen EJ, Borm GF et al. Pathological variants of focal segmental glomerulosclerosis in an adult Dutch populationepidemiology and outcome. Nephrol Dial Transplant 2008; 23: 186-192
17. Burnham K, Anderson D. Model Selection and Multimodel Inference. A Practical Information-Theoretic Approach, 2nd edn. Springer-Verlag, New York, 2002
18. Pencina MJ, D'Agostino RB, Pencina KM et al. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012; 176: 473-481
19. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research group on progressive renal diseases. Am J Kidney Dis 1997; 29: 526-532
20. Geddes CC, Rauta V, Gronhagen-Riska C et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003; 18: 1541-1548
21. Lv J, Zhang H, Zhou Y et al. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton) 2008; 13: 242-246
22. Kim JK, Kim JH, Lee SC et al. Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol 2012; 7: 427-436
23. Groenwold RH, Klungel OH, Altman DG et al. Adjustment for continuous confounders: an example of how to prevent residual confounding. CMAJ 2013; 185: 401-406
24. Royston P, Moons KG, Altman DG et al. Prognosis and prognostic research: developing a prognostic model. BMJ 2009; 338: b604
25. Tanaka S, Ninomiya T, Katafuchi R et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol 2013; 8: 2082-2090
26. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol 2013; 33: 14-22
27. Verbraecken J, Van de Heyning P, De Backer W et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006; 55: 515-524
28. Boyd E. The Growth of the Surface Area of the Human Body. University of Minnesota Press, Minneapolis, 1935
29. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
30. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011; 30: 22-38
31. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172; discussion 207-212.